Lenvima 4 Hard Capsules. Lenvima 10 Hard Capsules 4mg. 10mg Hard capsules
PDF Leaflet Revision Date: 27 June 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of advanced endometrial carcinoma, differentiated thyroid cancer, renal cell carcinoma, and unresectable hepatocellular carcinoma.
Dosage (summary)
24 mg daily for DTC; 20 mg daily for RCC with pembrolizumab; 8 mg daily for HCC (<60 kg) or 12 mg daily (u226560 kg).
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; may cause fetal harm.
Key Drug Interactions
- CYP3A4 inhibitors/inducers
- P-gp inhibitors/inducers
Contraindications
- Hypersensitivity to LENVIMA
- Severe uncontrolled hypertension
- Severe thrombocytopenia
- Active bleeding
- Fistulae
Common side effects
- Hypertension
- Fatigue
- Diarrhea
- Hypothyroidism
- Proteinuria
Counselling Points
- Monitor blood pressure regularly.
- Report any signs of bleeding or gastrointestinal issues.
- Avoid pregnancy and breastfeeding during treatment.
Serious warnings
- Gastrointestinal toxicity
- Renal failure
- Hypertension
- Cardiac dysfunction
- QT prolongation
Important Disclaimer
The Lenvima 4 Hard Capsules. Lenvima 10 Hard Capsules 4mg. 10mg Hard capsules professional information leaflet below is the property of Eisai Pharmaceuticals Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
